{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:29:17Z","timestamp":1787038157210,"version":"build-2736575974"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Agence Nationale de Recherche sur le sida et les h\u00e9patites virales I Maladies Infectieuses Emergentes"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Attachment inhibitor fostemsavir (FTR) and postattachment inhibitor ibalizumab (IBA) are used in people with HIV-1 (PWH) who are highly treatment experienced and harboring multidrug-resistant viruses, and real-world data remain limited. We describe population characteristics and pharmacovirologic outcomes of PWH initiating FTR- or IBA-based regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a French retrospective observational study within the AIDS Research National Agency | Emerging Infectious Diseases virology and pharmacology network. Virologic failure (VF) was defined as 2 consecutive plasma viral loads (VLs) \u226550 copies\/mL; nonvirologic response was considered a VL decrease &amp;lt;1 log10 copies\/mL or failure to achieve virologic suppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 70 PWH receiving FTR-based treatment, 50% were virologically suppressed at initiation; median VL among viremic cases was 3.6 log10 copies\/mL. Resistance to at least 2 antiretrovirals was observed among participants by inhibitor class: 96%, nucleoside reverse transcriptase inhibitor; 94%, nonnucleoside reverse transcriptase inhibitor; 74%, protease inhibitor; and 64%, integrase strand transfer inhibitor. The genotypic susceptibility score was \u22641 in 47%, and median follow-up was 20 months. Eight VFs and 8 nonvirologic responses occurred. At failure, emergence of FTR resistance-associated mutations occurred in 1 case. Suboptimal temsavir concentrations were observed in 2 of 8 participants in failure. Eleven PWH who were viremic initiated IBA-based treatment: the genotypic susceptibility score was \u22641 in 4, and median follow-up was 7 months with 5 VFs and 2 nonvirologic responses. One new resistance mutation (N74D, capsid) was detected at VF; suboptimal plasma concentrations of oral antiretrovirals were observed in 3 of 5 participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PWH receiving FTR or IBA had extensive multidrug resistance and limited therapeutic options. Among PWH who were viremic and initiating FTR- and IBA-based regimens, virologic success was achieved in 63% and 36%, respectively, and maintained in 91% who were virologically suppressed and starting an FTR-based regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag495","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:23:07Z","timestamp":1786706587000},"source":"Crossref","is-referenced-by-count":0,"title":["A French National Real-World Survey of People With Multiresistant HIV-1 Viruses Receiving an Antiretroviral Regimen Including Fostemsavir or Ibalizumab"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9686-9194","authenticated-orcid":false,"given":"Karl","family":"Stefic","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Tours, INSERM 1259 MAVIVHe, CHU de Tours, Service de Virologie , Tours ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Tumiotto","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de Virologie, CNRS-UMR 5234 Microbiologie Fondamentale et Pathog\u00e9nicit\u00e9, Universit\u00e9 de Bordeaux , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"de Monte","sequence":"additional","affiliation":[{"name":"CHU de Nice, Service de Virologie , Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3723-4142","authenticated-orcid":false,"given":"Marc","family":"Wirden","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, UMR-S 1136, Institut Pierre Louis D\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2013Charles Foix, Service de Virologie , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Rodallec","sequence":"additional","affiliation":[{"name":"CHU Nantes, Service de Virologie , Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djeneba","family":"Fofana","sequence":"additional","affiliation":[{"name":"Sant\u00e9 Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis D\u2019Epid\u00e9miologie et de Sant\u00e9 Publique APHP, H\u00f4pital Saint-Antoine, D\u00e9partement de Virologie , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7798-4621","authenticated-orcid":false,"given":"Marie-Laure","family":"Chaix","sequence":"additional","affiliation":[{"name":"Service de Virologie, INSERM U941, AP-HP, H\u00f4pital Saint-Louis, Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantxika","family":"Bellecave","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de Virologie, CNRS-UMR 5234 Microbiologie Fondamentale et Pathog\u00e9nicit\u00e9, Universit\u00e9 de Bordeaux , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Garnier","sequence":"additional","affiliation":[{"name":"CHU Nantes, Service de Virologie , Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5657-842X","authenticated-orcid":false,"given":"Justine","family":"Sourice","sequence":"additional","affiliation":[{"name":"CHU Nantes, Service de Virologie , Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-6695","authenticated-orcid":false,"given":"Camille","family":"Vellas","sequence":"additional","affiliation":[{"name":"INSERM UMR 1291, CHU Toulouse Purpan, Service de Virologie , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3780-5844","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Raymond","sequence":"additional","affiliation":[{"name":"INSERM UMR 1291, CHU Toulouse Purpan, Service de Virologie , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidonie","family":"Lambert-Niclot","sequence":"additional","affiliation":[{"name":"Sant\u00e9 Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis D\u2019Epid\u00e9miologie et de Sant\u00e9 Publique APHP, H\u00f4pital Saint-Antoine, D\u00e9partement de Virologie , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1106-9826","authenticated-orcid":false,"given":"Enagnon Kazali","family":"Alidjinou","sequence":"additional","affiliation":[{"name":"Univ Lille, CHU de Lille, Laboratoire de Virologie ULR3610 , Lille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0011-3342","authenticated-orcid":false,"given":"Pauline","family":"Coulon","sequence":"additional","affiliation":[{"name":"Univ Lille, CHU de Lille, Laboratoire de Virologie ULR3610 , Lille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-2990","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Avettand-Fenoel","sequence":"additional","affiliation":[{"name":"Universit\u00e9 d\u2019Orl\u00e9ans, LI2RSO, CHU d\u2019Orl\u00e9ans, Service de Virologie , Orl\u00e9ans ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Mchantaf","sequence":"additional","affiliation":[{"name":"Universit\u00e9 d\u2019Orl\u00e9ans, LI2RSO, CHU d\u2019Orl\u00e9ans, Service de Virologie , Orl\u00e9ans ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Handala","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Tours, INSERM 1259 MAVIVHe, CHU de Tours, Service de Virologie , Tours ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8906-3416","authenticated-orcid":false,"given":"Elodie","family":"Alessandri-Gradt","sequence":"additional","affiliation":[{"name":"Univ Rouen Normandie, Universit\u00e9 de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 11, CHU Rouen, Department of Virology, National Reference Center of HIV , Rouen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Moisan","sequence":"additional","affiliation":[{"name":"Univ Rouen Normandie, Universit\u00e9 de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 11, CHU Rouen, Department of Virology, National Reference Center of HIV , Rouen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh","family":"L\u00ea","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie, AP-HP, H\u00f4pital Bichat-Claude Bernard, Universit\u00e9 Paris Cit\u00e9, INSERM, IAME , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Delaugerre","sequence":"additional","affiliation":[{"name":"Service de Virologie, INSERM U941, AP-HP, H\u00f4pital Saint-Louis, Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-8999","authenticated-orcid":false,"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, UMR-S 1136, Institut Pierre Louis D\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2013Charles Foix, Service de Virologie , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-537X","authenticated-orcid":false,"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie, AP-HP, H\u00f4pital Bichat-Claude Bernard, Universit\u00e9 Paris Cit\u00e9, INSERM, IAME , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, UMR-S 1136, Institut Pierre Louis D\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2013Charles Foix, Service de Virologie , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"Service de Virologie, AP-HP, H\u00f4pital Bichat-Claude Bernard, Universit\u00e9 Paris Cit\u00e9, INSERM, IAME , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"Service de Virologie, AP-HP, H\u00f4pital Bichat-Claude Bernard, Universit\u00e9 Paris Cit\u00e9, INSERM, IAME , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Entry Inhibitors Observatory Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Allavena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Bachelard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Cazanave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chirio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Conan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Cua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Delobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Hocqueloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estibalitz","family":"Lazaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Lemaignen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Martin-Blondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Phung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Pourcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Proux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayda","family":"Rahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Rioux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Robineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2026081803215503600_ofag495-B1","doi-asserted-by":"crossref","first-page":"106956","DOI":"10.1016\/j.ijid.2024.01.023","article-title":"Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options\u2014the ICONA Foundation cohort study","volume":"143","author":"Lo Caputo","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2026081803215503600_ofag495-B2","doi-asserted-by":"crossref","first-page":"ofab562","DOI":"10.1093\/ofid\/ofab562","article-title":"Characterization of heavily treatment-experienced people with HIV and impact on health care resource utilization in US commercial and Medicare advantage health plans","volume":"8","author":"Priest","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026081803215503600_ofag495-B3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/QAI.0000000000002635","article-title":"Prevalence and outcomes for heavily treatment-experienced individuals living with human immunodeficiency virus in a European cohort","volume":"87","author":"Pelchen-Matthews","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026081803215503600_ofag495-B4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1473-3099(06)70550-3","article-title":"Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults","volume":"6","author":"Temesgen","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"2026081803215503600_ofag495-B5","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/QAD.0000000000002679","article-title":"Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options","volume":"34","author":"Bajema","year":"2020","journal-title":"AIDS"},{"key":"2026081803215503600_ofag495-B6","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1093\/cid\/ciaf204","article-title":"Drug resistance in people with viremia on dolutegravir-based antiretroviral therapy in sub-Saharan Africa: the DTG RESIST study","volume":"81","author":"Loosli","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026081803215503600_ofag495-B7","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1016\/S2214-109X(24)00553-9","article-title":"Predicted dolutegravir resistance in people living with HIV in South Africa during 2020\u201335: a modelling study","volume":"13","author":"Loosli","year":"2025","journal-title":"Lancet Glob Health"},{"key":"2026081803215503600_ofag495-B8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/AAC.00942-08","article-title":"Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1\u2013infected adults","volume":"53","author":"Jacobson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081803215503600_ofag495-B9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1128\/AAC.01173-10","article-title":"In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043","volume":"55","author":"Zhou","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081803215503600_ofag495-B10","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/S2352-3018(15)00177-0","article-title":"Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial","volume":"2","author":"Lalezari","year":"2015","journal-title":"Lancet HIV"},{"key":"2026081803215503600_ofag495-B11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N Engl J Med"},{"key":"2026081803215503600_ofag495-B12","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"2026081803215503600_ofag495-B13","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"key":"2026081803215503600_ofag495-B14","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.00426-12","article-title":"In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068","volume":"56","author":"Nowicka-Sans","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081803215503600_ofag495-B15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/dkt412","article-title":"Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068","volume":"69","author":"Zhou","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026081803215503600_ofag495-B16","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1016\/S2352-3018(20)30240-X","article-title":"Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study","volume":"7","author":"Lataillade","year":"2020","journal-title":"Lancet HIV"},{"key":"2026081803215503600_ofag495-B17","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in adults with multidrug-resistant HIV-1 infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N Engl J Med"},{"key":"2026081803215503600_ofag495-B18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/QAI.0b013e31829726f3","article-title":"Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068","volume":"64","author":"Ray","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026081803215503600_ofag495-B19","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/hiv.70154","article-title":"Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study","volume":"27","author":"Gartland","year":"2026","journal-title":"HIV Med"},{"key":"2026081803215503600_ofag495-B20","doi-asserted-by":"crossref","first-page":"e0175121","DOI":"10.1128\/aac.01751-21","article-title":"Week 96 genotypic and phenotypic results of the fostemsavir phase 3 BRIGHTE study in heavily treatment-experienced adults living with multidrug-resistant HIV-1","volume":"66","author":"Gartland","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081803215503600_ofag495-B21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1086\/380802","article-title":"Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1","volume":"189","author":"Kuritzkes","year":"2004","journal-title":"J Infect Dis"},{"key":"2026081803215503600_ofag495-B22","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.4049\/jimmunol.149.5.1779","article-title":"Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion","volume":"149","author":"Burkly","year":"1992","journal-title":"J Immunol"},{"key":"2026081803215503600_ofag495-B23","doi-asserted-by":"crossref","first-page":"e00110-19","DOI":"10.1128\/AAC.00110-19","article-title":"Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection","volume":"63","author":"Beccari","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081803215503600_ofag495-B24","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.00761-05","article-title":"Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20)","volume":"50","author":"Zhang","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081803215503600_ofag495-B25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/QAD.0000000000003218","article-title":"Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates","volume":"36","author":"Le Hingrat","year":"2022","journal-title":"AIDS"},{"key":"2026081803215503600_ofag495-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0b013e3182732746","article-title":"Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope","volume":"62","author":"Pace","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026081803215503600_ofag495-B27","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1128\/JVI.02237-10","article-title":"Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab","volume":"85","author":"Toma","year":"2011","journal-title":"J Virol"},{"key":"2026081803215503600_ofag495-B28","first-page":"457","article-title":"2025 Update of the drug resistance mutations in HIV-1","volume":"33","author":"Wensing","year":"2025","journal-title":"Top Antivir Med"},{"issue":"e-1","key":"2026081803215503600_ofag495-B29","first-page":"49","article-title":"HIV-1 attachment inhibitor prodrug BMS-663068: model-based dose selection.","volume":"23","author":"Savant Landry","year":"2015","journal-title":"Top Antivir Med"},{"key":"2026081803215503600_ofag495-B30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hiv.13700","article-title":"Immunological and virological response to fostemsavir in routine US clinical care: an OPERA cohort study","volume":"26","author":"Hsu","year":"2025","journal-title":"HIV Med"},{"key":"2026081803215503600_ofag495-B31","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/QAD.0000000000002851","article-title":"Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1","volume":"35","author":"Ackerman","year":"2021","journal-title":"AIDS"},{"key":"2026081803215503600_ofag495-B32","doi-asserted-by":"crossref","first-page":"1394644","DOI":"10.3389\/fimmu.2024.1394644","article-title":"Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study","volume":"15","author":"Llibre","year":"2024","journal-title":"Front Immunol"},{"key":"2026081803215503600_ofag495-B33","first-page":"5","article-title":"Fostemsavir in a real-world setting: over one year of data from the PRESTIGIO registry.","volume":"26","author":"Papaioannu Borjesson","year":"2025","journal-title":"HIV Med"},{"key":"2026081803215503600_ofag495-B34","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1093\/cid\/ciaf597","article-title":"Combined use of ibalizumab and lenacapavir for the treatment of multidrug-resistant HIV-1: a case series","volume":"82","author":"Rolle","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026081803215503600_ofag495-B35","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003699","article-title":"Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: a phase 3, multicenter, expanded access study","author":"Emu","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026081803215503600_ofag495-B36","doi-asserted-by":"crossref","first-page":"103906","DOI":"10.1016\/j.ebiom.2022.103906","article-title":"Achieving virological control in pan-resistant HIV-1 infection: a case series","volume":"77","author":"Canetti","year":"2022","journal-title":"EBioMedicine"},{"key":"2026081803215503600_ofag495-B37","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/QAI.0000000000002591","article-title":"Efficacy, pharmacokinetics, and safety over 48 weeks with ibalizumab-based therapy in treatment-experienced adults infected with HIV-1: a phase 2a study","volume":"86","author":"Gathe","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026081803215503600_ofag495-B38","doi-asserted-by":"crossref","DOI":"10.2471\/B09471","volume-title":"Overview of WHO recommendations on HIV and sexually transmitted infection testing, prevention, treatment, care and service delivery","author":"World Health Organization","year":"2025"},{"key":"2026081803215503600_ofag495-B39","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkaa474","article-title":"Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense entry assay","volume":"76","author":"Gartland","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026081803215503600_ofag495-B40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/COH.0000000000000798","article-title":"Development of screening assays for use of broadly neutralizing antibodies in people with HIV","volume":"18","author":"Lynch","year":"2023","journal-title":"Curr Opin HIV AIDS"},{"key":"2026081803215503600_ofag495-B41","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/infdis\/jiae486","article-title":"Evaluation and real-world experience of a neutralization susceptibility screening assay for broadly neutralizing anti-HIV-1 antibodies","volume":"231","author":"Pahus","year":"2025","journal-title":"J Infect Dis"},{"key":"2026081803215503600_ofag495-B42","first-page":"20499361251325103","article-title":"Fostemsavir resistance in clinical context: a narrative review","volume":"12","author":"Schapiro","year":"2025","journal-title":"Ther Adv Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag495\/70650762\/ofag495.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag495\/70650762\/ofag495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag495\/70650762\/ofag495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:22:07Z","timestamp":1787037727000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag495\/8761652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag495","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8,1]]},"article-number":"ofag495"}}